Qi Xingshun, Ren Weirong, Wang Yongji, Guo Xiaozhong, Fan Daiming
Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, 110840, China.
Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):865-75. doi: 10.1586/17474124.2015.1024224. Epub 2015 Mar 10.
This paper aimed to systematically review the survival of Budd-Chiari syndrome and to identify the most robust prognostic predictors. Overall, 79 studies were included. According to the treatment modalities, the median 1-, 5- and 10-year survival rate was 93, 83 and 73% after interventional radiological treatment; 81, 75 and 72.5% after surgery other than liver transplantation; 82.5, 70.2 and 66.5% after liver transplantation and 68.1, 44.4% and unavailable after medical therapy alone. According to the publication years, the median 1-, 5- and 10-year survival rate was 68.6, 44.4% and unavailable before 1990; 75.1, 69.5 and 57% during the year 1991-1995; 77, 69.6 and 65.6% during the year 1996-2000; 86.5, 74 and 63.5% during the year 2001-2005 and 90, 82.5 and 72% after 2006. Bilirubin, creatinine and ascites were more frequently identified as significant prognostic factors in univariate analyses. But their statistical significance was less frequently achieved in multivariate analyses.
本文旨在系统评价布加综合征的生存率,并确定最可靠的预后预测因素。总体而言,共纳入79项研究。根据治疗方式,介入放射治疗后1年、5年和10年的中位生存率分别为93%、83%和73%;非肝移植手术治疗后分别为81%、75%和72.5%;肝移植后分别为82.5%、70.2%和66.5%;单纯药物治疗后分别为68.1%、44.4%,10年生存率未提及。根据发表年份,1990年前1年、5年和10年的中位生存率分别为68.6%、44.4%,10年生存率未提及;1991 - 1995年分别为75.1%、69.5%和57%;1996 - 2000年分别为77%、69.6%和65.6%;2001 - 2005年分别为86.5%、74%和63.5%;2006年后分别为90%、82.5%和72%。在单因素分析中,胆红素、肌酐和腹水更常被确定为显著的预后因素。但在多因素分析中,它们的统计学意义较难达到。